GYRE

Business Context and Reporting Period

Gyre Therapeutics, Inc. (GYRE) is a commercial-stage biotechnology company focused on developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs. The company operates primarily through its subsidiary, Gyre Pharmaceuticals, in the People's Republic of China (PRC), with a U.S. presence focused on the development of F351 for liver fibrosis. This summary covers the quarterly period ended March 31, 2025.

Key Financial Metrics

Liquidity: As of March 31, 2025, the company held $15.0 million in cash and cash equivalents, $14.8 million in short-term bank deposits, and $21.4 million in long-term certificates of deposit. Management believes these resources are sufficient to fund operations for at least the next 12 months.

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased by 19% ($5.1 million) compared to Q1 2024. This was primarily due to a $5.2 million decline in sales of the flagship product ETUARY (pirfenidone), attributed to the absence of a one-time rural expansion marketing campaign conducted in early 2024, increased competition, and weaker economic conditions in China.
• Expense Increases:
  • R&D Expenses: Increased 42% ($0.9 million) driven by a $1.3 million rise in clinical research expenses, specifically for data analysis of the F351 Phase 3 trial.
  • G&A Expenses: Increased 46% ($1.6 million) due to higher personnel costs, stock-based compensation, and annual meeting expenses.
• Non-Operating Income: The gain from the change in fair value of warrant liability decreased by 47% ($2.0 million) to $2.3 million, reflecting the remeasurement of Preferred Stock Warrants.
• Intangible Assets: Intangible assets increased significantly from $0.3 million to $5.1 million due to the recognition of Nintedanib technology rights ($4.9 million) following the transfer of marketing authorization in March 2025.

Outlook, Risks, and Management Commentary

• Product Pipeline & Launches:
  • Nintedanib: Commercialization is planned for Q2 2025 to offset ETUARY sales declines. The company acquired IP rights for this IPF treatment.
  • F351: The Phase 3 trial for CHB-associated liver fibrosis in the PRC has completed data collection, with topline results expected in Q2 2025. A Phase 2 trial for MASH-associated liver fibrosis in the U.S. is expected to initiate in 2025, pending IND approval and potential additional capital raising.
  • Avatrombopag: Commercialization began in March 2025, generating initial revenue.
• Capital Markets: The company initiated an At-The-Market (ATM) program in November 2024 with up to $50.0 million in gross proceeds. In Q1 2025, it sold 54,734 shares for net proceeds of $0.5 million.
• Risks:
  • Concentration Risk: Three customers (Sinopharm, Resources Pharmaceutical, Shanghai Pharmaceuticals) accounted for approximately 78% of revenue in Q1 2025. Sinopharm alone represented 50.3% of revenue.
  • Foreign Currency: Significant cash holdings are denominated in RMB, subject to exchange rate fluctuations and PRC foreign exchange controls.
  • Regulatory & Clinical: Future funding requirements depend on the success of clinical trials and regulatory approvals, particularly for F351 in the U.S.

Investor Verification Checklist

• Revenue Sustainability: Verify the impact of the Nintedanib launch in Q2 2025 on offsetting the decline in ETUARY sales.
• Cash Burn vs. Runway: Confirm the sufficiency of the $51.2 million in total liquid assets (cash, short-term deposits, long-term CDs) to fund the planned U.S. Phase 2 trial for F351 without immediate dilution.
• Customer Concentration: Assess the risk associated with Sinopharm representing over 50% of revenue and 53.5% of accounts receivable.
• Warrant Liability Volatility: Monitor the fair value of the remaining $3.4 million warrant liability, which impacts net income but not cash flow.
• Contingent Payments: Review the terms of the Nintedanib IP agreement, which includes annual contingent payments based on future sales over eight years.